I don't disagree with you, but I think we should wait and learn more about the bigger picture before we get carried away. Loads of drugs are extremely promising, until they fail. I'm by no means saying FX-322 is going to fail, but I try not to get carried away on either end of the spectrum. At the moment, it's a wait and observe scenario.
We'll know a lot more once the data from phase 2a has been analysed and released, possibly towards the end of this year or maybe next. I don't think it's wise to be convinced of what this drug can do at this early stage. Let the hype commence once it smashes phase 3.
I've invested in many sure-things that have failed in the past and this includes biomedical shares. That's why, for me at least, I'll only become emotionally involved once it's clinically proven to help tinnitus and/or hyperacusis. Until then, it's all about following the research with a neutral mindset.